According to reports, GENFLEET-B (02595) experienced a drop of over 8% in the afternoon, but rebounded to increase by more than 9% near the market close. As of the time of reporting, the stock rose 6.71%, trading at HKD 28.3, with a transaction volume of HKD 44.5183 million. The company announced that its oral high-activity and highly selective small molecule KRAS G12D (ON/OFF) inhibitor GFH375 has completed the first patient enrollment in its Phase Ib/II study for the treatment of advanced solid tumors with KRAS G12D mutations, at Peking University Cancer Hospital. This study received clinical trial approval from the National Medical Products Administration in September this year and involves two combination therapies: one with cetuximab and another with chemotherapy, where the GFH375 and chemotherapy regimen is a first-line treatment scheme for pancreatic ductal adenocarcinoma (PDAC). It is noteworthy that data from the GFH375 monotherapy for KRAS G12D mutant PDAC patients was showcased on October 19 in the breakthrough research abstract and oral presentation at the 2025 ESMO annual meeting. The oral presentation was conducted by Professor Zhou Aiping from the Chinese Academy of Medical Sciences Cancer Hospital, titled “Efficacy and Safety of GFH375 in Patients with Metastatic KRAS G12D Mutant PDAC.” The report focused on research data from the 600 mg QD (RP2D) dose group of PDAC patients, demonstrating that GFH375 offers significant efficacy and controllable safety for treating PDAC patients. For more significant updates on Hong Kong stocks, download the Zhitong Finance app for further Hong Kong and overseas financial information by visiting www.zhitongcaijing.com (search for “Zhitong Finance”); to join the Zhitong Hong Kong stock investment group, please add Zhitong customer service WeChat (ztcjkf).